

Current and Future Trends in Pharmaceutical Compounding

How did we get to where we are now? Have all the changes been unfavorable? Or beneficial? Or a combination? The important aspect is “What have we learned?” Pharmacists will continue to experience change, but the industry can influence future change for 503A pharmacies at the state board of pharmacy level and 503B Outsourcing Facilities at the federal level. Compounding continues to grow, quality issues continue to be addressed, and we must continually rise to the challenges it presents.



Loyd V. Allen, Jr., PhD, RPh
Editor-in-Chief, International Journal of Pharmaceutical Compounding, CompoundingToday.com, Remington-The Science and Practice of Pharmacy

Dr. Allen is Editor-in-Chief of the International Journal of Pharmaceutical Compounding (IJPC) and Remington-The Science and Practice of

Pharmacy, CEO of the Midwest Institute of Research and Technology and Professor Emeritus of the University of Oklahoma College of Pharmacy. He obtained his B.S. and M.S. in Pharmacy from the University of Oklahoma College of Pharmacy in 1966 and 1970, respectively. He completed a residency in hospital pharmacy at the U.S. Public Health Service Hospital in Boston, MA in 1966-67. He received the Ph.D. in Pharmaceutics from the University of Texas at Austin in 1972.

He taught at the University of Oklahoma College of Pharmacy for 30 years where he was Professor and Chair, Department of Medicinal Chemistry and Pharmaceutics. In 1996, he founded the IJPC, and serves as Editor-in-Chief. In addition, he is a consultant in pharmacy and pharmaceutics to the pharmaceutical industry in product development and patent infringement legal cases.

Dr. Allen is a Fellow of numerous organizations, has received numerous awards and has served as a member of the U.S. Pharmacopeia Committee of Revision/Expert Committees for 35 years. He has served in numerous positions in the APhA Academy of Pharmaceutical Research and Science and served on the APhA Board of Trustees for 1999-2000. His research interests are in the areas of drug dosage form design/development and drug stability/compatibility. He is currently working on both national and international projects involving new drug product formulation.

He supervised 25 M.S. and Ph.D. students. In addition, he has been awarded 13 U.S. patents in the field of drug formulations, both nationally and internationally. He has over 200 experimental publications and abstracts; 25 book editions, chapters and monographs; over 500 professional publications; co-author on 3 textbooks and sole author of 2 textbooks, two of which are in numerous editions and in multiple languages.